{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:23:03Z","timestamp":1790364183062,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001232","name":"Royal Australasian College of Physicians","doi-asserted-by":"publisher","award":["GNT1111657"],"award-info":[{"award-number":["GNT1111657"]}],"id":[{"id":"10.13039\/501100001232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.vaccine.2020.06.039","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T01:51:12Z","timestamp":1595382672000},"page":"6038-6046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Adverse events following HPV vaccination: 11\u00a0years of surveillance in Australia"],"prefix":"10.1016","volume":"38","author":[{"given":"Anastasia","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Hickie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9459-2566","authenticated-orcid":false,"given":"James","family":"Totterdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-3105","authenticated-orcid":false,"given":"Julia","family":"Brotherton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7178-8606","authenticated-orcid":false,"given":"Aditi","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4670-0638","authenticated-orcid":false,"given":"Tom","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.06.039_b0005","doi-asserted-by":"crossref","first-page":"614","DOI":"10.5694\/mja13.10272","article-title":"Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach","volume":"199","author":"Brotherton","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2020.06.039_b0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s13669-016-0165-z","article-title":"Primary Prevention of HPV through Vaccination: Update on the Current Global Status","volume":"5","author":"Brotherton","year":"2016","journal-title":"Curr Obstet Gynecol Rep"},{"key":"10.1016\/j.vaccine.2020.06.039_b0015","doi-asserted-by":"crossref","first-page":"1700737","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","volume":"23","author":"Patel","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2020.06.039_b0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/528009a","article-title":"The world must accept that the HPV vaccine is safe","volume":"528","author":"Larson","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.06.039_b0025","first-page":"306","article-title":"Global Advisory Committee on Vaccine Safety, 5\u20136 June 2019","volume":"28","author":"World Health Organisation","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2020.06.039_b0030","unstructured":"National HPV Vaccination Program Register. Coverage Data. Victorian Cytology Service. <http:\/\/www.hpvregister.org.au\/research\/coverage-data>[Accessed: 14 September 2019]."},{"key":"10.1016\/j.vaccine.2020.06.039_b0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40264-017-0625-z","article-title":"Safety of Human Papillomavirus Vaccines: An Updated Review","volume":"41","author":"Phillips","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.06.039_b0040","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1080\/21645515.2016.1168952","article-title":"Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States","volume":"12","author":"Gee","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.06.039_b0045","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2 million young girls in France","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0050","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.vaccine.2010.09.020","article-title":"Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006\u20132009","volume":"29","author":"Souayah","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.06.039_b0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barre syndrome after human papilloma virus vaccine: A self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstrom","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2020.06.039_b0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14760584.2018.1388168","article-title":"Absence of association between Guillain-Barre syndrome hospitalizations and HPV-vaccine","volume":"17","author":"Deceuninck","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.06.039_b0075","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/ije\/dyx273","article-title":"Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism","volume":"47","author":"Frisch","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.06.039_b0080","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1016\/j.vaccine.2017.09.009","article-title":"Risk of Guillain-Barre Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink","volume":"35","author":"Gee","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0085","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.vaccine.2015.10.006","article-title":"Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008\u20132011","volume":"34","author":"Naleway","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.2014.2198","article-title":"Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism","volume":"312","author":"Scheller","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.06.039_b0095","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.vaccine.2015.09.087","article-title":"Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females","volume":"34","author":"Yih","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0100","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1016\/j.vaccine.2013.08.024","article-title":"Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK","volume":"31","author":"Donegan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0105","unstructured":"European Medicines Agency. Assessment Report: Review under Article 20 of Regulation (EC) No 726\/2004, Human papillomavirus (HPV) vaccines. London: 2015. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/HPV_vaccines_20\/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use\/WC500197129.pdf>."},{"key":"10.1016\/j.vaccine.2020.06.039_b0110","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2017.06.031","article-title":"HPV vaccination and risk of chronic fatigue syndrome\/myalgic encephalomyelitis: A nationwide register-based study from Norway","volume":"35","author":"Feiring","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0115","series-title":"Statement on Safety of HPV vaccines","author":"Global Advisory Committee on Vaccine safety","year":"2015"},{"key":"10.1016\/j.vaccine.2020.06.039_b0120","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-0943","article-title":"Primary Ovarian Insufficiency and Adolescent Vaccination","volume":"142","author":"Naleway","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.06.039_b0125","unstructured":"Committee to Review Adverse Effects of Vaccines Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Washington (DC): National Academies Press (US); 2011."},{"key":"10.1016\/j.vaccine.2020.06.039_b0130","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0135","unstructured":"World Health Organisation. Global manual on surveillance of adverse events following immunisation. Geneva: World Health Organisation; 2016 <https:\/\/www.who.int\/vaccine_safety\/publications\/aefi_surveillance\/en\/>."},{"key":"10.1016\/j.vaccine.2020.06.039_b0140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1503\/cmaj.080916","article-title":"Anaphylaxis following quadrivalent human papillomavirus vaccination","volume":"179","author":"Brotherton","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2020.06.039_b0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458508096868","article-title":"CNS demyelination and quadrivalent HPV vaccination","volume":"15","author":"Sutton","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.vaccine.2020.06.039_b0150","unstructured":"Therapeutic Goods Administration. Gardasil (human papillomavirus vaccine). Australian Government Department of Health. <https:\/\/www.tga.gov.au\/alert\/gardasil-human-papillomavirus-vaccine>[Accessed: 14 September 2019]."},{"key":"10.1016\/j.vaccine.2020.06.039_b0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5694\/j.1326-5377.2008.tb02018.x","article-title":"Mass psychogenic response to human papillomavirus vaccination","volume":"189","author":"Buttery","year":"2008","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2020.06.039_b0160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5694\/j.1326-5377.2011.tb04138.x","article-title":"Syncope and seizures following human papillomavirus vaccination: a retrospective case series","volume":"194","author":"Crawford","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2020.06.039_b0165","unstructured":"Therapeutic Goods Administration. Enhanced school-based surveillance of acute adverse events following immunisation with human papillomavirus vaccine in males and females, 2013. Canberra: Australian Government Department of Health; 2015.<https:\/\/www.tga.gov.au\/enhanced-school-based-surveillance-acute-adverse-events-following-immunisation-human-papillomavirus-vaccine-males-and-females-2013>."},{"key":"10.1016\/j.vaccine.2020.06.039_b0170","unstructured":"National Centre for Immunisation Research and Surveillance. Vaccine Safety. NCIRS. <http:\/\/www.ncirs.org.au\/health-professionals\/vaccine-safety>[Accessed: 12 January 2020]."},{"key":"10.1016\/j.vaccine.2020.06.039_b0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.06.039_b0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.vaccine.2014.11.047","article-title":"Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006\u20132013","volume":"33","author":"Moro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0185","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.vaccine.2018.02.034","article-title":"Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009\u20132015","volume":"36","author":"Arana","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0190","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-003-1096-y","article-title":"Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barre syndrome","volume":"250","author":"Odaka","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.vaccine.2020.06.039_b0195","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0200","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.hrthm.2015.03.029","article-title":"2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope","volume":"12","author":"Sheldon","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.vaccine.2020.06.039_b0205","article-title":"Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice","volume":"2","author":"Little","year":"2014","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.vaccine.2020.06.039_b0210","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/archdischild-2011-301307","article-title":"Complex regional pain syndrome following immunisation","volume":"97","author":"Richards","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2020.06.039_b0215","doi-asserted-by":"crossref","DOI":"10.33321\/cdi.2019.43.29","article-title":"Surveillance of adverse events following immunisation in Australia annual report, 2017","volume":"43","author":"Dey","year":"2019","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.vaccine.2020.06.039_b0220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7812\/TPP\/17-136","article-title":"Development of an Intervention to Reduce Pain and Prevent Syncope Related to Adolescent Vaccination","volume":"23","author":"Kuntz","year":"2019","journal-title":"Perm J"},{"key":"10.1016\/j.vaccine.2020.06.039_b0225","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.vaccine.2015.02.008","article-title":"Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013","volume":"33","author":"Cheng","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0230","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.vaccine.2014.01.004","article-title":"Adverse events following immunization in Ontario's female school-based HPV program","volume":"32","author":"Harris","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0235","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/INF.0000000000001073","article-title":"Anaphylaxis After Immunization of Children and Adolescents in Germany","volume":"35","author":"Oberle","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.06.039_b0240","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1503\/cmaj.071134","article-title":"Autoimmune diseases after adolescent or adult immunization: what should we expect?","volume":"177","author":"Siegrist","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2020.06.039_b0245","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1440-1754.2003.00065.x","article-title":"Acute flaccid paralysis in Australian children","volume":"39","author":"Morris","year":"2003","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.vaccine.2020.06.039_b0250","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jadohealth.2017.08.004","article-title":"Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System","volume":"61","author":"Arana","year":"2017","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2020.06.039_b0255","first-page":"393","article-title":"Meeting of the Global Advisory Committee on Vaccine Safety, 7\u20138 June 2017","volume":"92","author":"World Health Organisation","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2020.06.039_b0260","article-title":"Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society","author":"Barboi","year":"2019","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.vaccine.2020.06.039_b0265","first-page":"24","article-title":"to August 2017","volume":"2019","author":"Ward","year":"2009","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2020.06.039_b0270","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.vaccine.2015.04.014","article-title":"Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine","volume":"33","author":"Goss","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.06.039_b0275","doi-asserted-by":"crossref","DOI":"10.33321\/cdi.2020.44.12","article-title":"Surveillance of adverse events following immunisation in Australia annual report, 2018","volume":"44","author":"Dey","year":"2020","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.vaccine.2020.06.039_b0280","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/INF.0000000000000983","article-title":"Global Vaccine Safety Assessment: Challenges and Opportunities","volume":"35","author":"Tomianovic","year":"2016","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:16:23Z","timestamp":1777536983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20308252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":56,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0264410X20308252"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following HPV vaccination: 11\u00a0years of surveillance in Australia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}